Ain Shams University
Cairo, Abbasiyah, 00202, Egypt
NCT Number: NCT07475143
The aim of this work is to compare the outcome of Single Anastomosis Sleeve Jejunal Bypass (SASJ) with One Anastomosis Gastric Bypass (OAGB) as regards effect on levels of GLP-1 mainly, PYY and GIP and subsequent effect on insulin resistance and Type II diabetes mellitus resolution.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Cairo, Abbasiyah, 00202, Egypt
The aim of this work is to compare the outcome of Single Anastomosis Sleeve Jejunal Bypass (SASJ) with One Anastomosis Gastric Bypass (OAGB) as regards effect on levels of GLP-1 (as a primary outcome), PYY and GIP and subsequent effect on insulin resistance and Type II diabetes mellitus resolution.
SASJ Group: composed of 20 patients undergoing SASJ operation. - OAGB Group: composed of 20 patients undergoing OAGB operation.
Convenience sampling was used and the sample size was 40 patients. An informed consent was taken from all patients and all data are confidential, and patients will not be mentioned by name in any published paper. Patients will have the right to refuse joining the research or withdraw at any time without affecting their chance to receive the traditional therapy at any time.
Regarding the Study Procedures, all patients will have preoperative workup including full history taking, general and local examination, laboratory profile including complete blood picture, liver function tests, kidney function tests, clotting profile, fasting and 2-hour postprandial blood glucose, HbA1C, serum insulin level, C-peptide (in non-insulin receiving patients) and Viral markers. Also Serum levels of GLP-1, PYY and GIP, thyroid profile (Free T3, T4 and TSH), pelviabdominal US, and upper GI endoscopy in patients with GERD or when an intra-gastric pathology is suspected. Cardiopulmonary assessment could be done if clinically indicated.
Operative details - One anastomosis gastric bypass includes creation of a proximal gastric pouch and a stapled side to side gastrojejunostomy anastomosis (4.5 cm staple) is made within 200 cm from the ligament of Treitz and below the level of crow's foot. A transverse anastomosis is usually done.
Single anastomosis sleeve jejunal bypass (SASJ) is a new operation for morbid obesity. The investigators will do sleeve gastrectomy using a bougie with the size of 36 Fr primarily. Then, the gastrojejunostomy anastomosis is made within 200 cm from the ligament of Treitz and the selected loop was stapled side to side (4.5 cm staple) within 6 cm or more away from the pylorus.
Regarding postoperative follow up, routine follow up visits will be arranged after one month, 3 months and 6 months. Also serum levels of GLP-1, PYY and GIP will be measured 6-8 weeks post-operative. In each visit patient will have full clinical assessment including glycemic control especially HbA1c levels, fasting blood glucose levels, post prandial serum glucose levels, serum insulin levels, C peptide levels (in non-insulin receiving patients), weight loss rate and total weight loss percentage calculated with nutritional parameters like serum calcium, iron, albumin, vitamin D and PTH will be assessed once after 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single anastomosis sleeve jejunal bypass (SASJ) is a new operation for morbid obesity. The investigator will do sleeve gastrectomy using a bougie with the size of 36 Fr primarily. Then, the gastrojejunostomy anastomosis is made within 200 cm from the ligament of Treitz and the selected loop was stapled side to side (4.5 cm staple) within 6 cm or more away from the pylorus.
Other names: SASJ
One anastomosis gastric bypass includes creation of a proximal gastric pouch and a stapled side to side gastrojejunostomy anastomosis (4.5 cm staple) is made within 200 cm from the ligament of Treitz and below the level of crow's foot.
Other names: OAGB, MGB, Mini-gastric Bypass
Time frame: Serum levels of GLP-1 will be measured 6-8 weeks post-operative, with routine follow up visits planned for 1 year post-operative.
Plasma levels of Incretin GLP-1 are measured before and after the assigned operation using ELISA kits.GLP-1 levels will be measured using (pmol/L) unit.
Time frame: 6-8 weeks post operative
Plasma levels of Incretin GIP are measured before and after the assigned operation using ELISA kits.GIP levels will be measured using (pmol/L) unit.
Serum levels of GIP will be measured 6-8 weeks post-operative, with routine follow up visits planned for 1 year post-operative.
Time frame: 6-8 weeks post operative
Plasma levels of Incretin PYY are measured before and after the assigned operation using ELISA kits. Serum levels will be measured using (pmol/L) unit.
Serum levels of PYY will be measured 6-8 weeks post-operative, with routine follow up visits planned for 1 year post-operative.
Time frame: 6-8 weeks post operative
Measurement of total weight loss percentage (TWL%) 6-8 weeks post operative.
Time frame: 6-8 weeks post operative
Full clinical assessment including fasting blood glucose levels in mg/dL
Time frame: 6-8 weeks post operative
Full clinical assessment including 2 hour post-prandial blood glucose levels in mg/dL.
Time frame: 6-8 weeks post operative
Blood HbA1c levels in percentage
Ain Shams University
Other
Single Anastomosis Sleeve Jejunal Bypass VS One Anastomosis/Mini Gastric Bypass as Regards GLP-1, PYY, GIP, Insulin Resistance and Type II Diabetes Mellitus Resolution: A Prospective Partially Randomized Patient Preference Comparative Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02150356
Glucose and Lipid Metabolism, Incretin Hormones Plasma Levels
Naples, Italy
View Trial DetailsNCT00571220
Body Weight, Diabetes Mellitus
New York, United States
View Trial DetailsNCT06406439
Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes Mellitus
Gwangmyeong, Deokan-ro, South Korea
View Trial DetailsNCT00038727
Body Weight, CVD
Rockville, Maryland, United States
View Trial Details